The agency OK’d generic versions of Lyrica, pregabalin, to Alembic Pharmaceuticals, Alkem Laboratories, Amneal Pharmaceuticals, Dr. Reddy’s Laboratories, InvaGen Pharmaceuticals, MSN Laboratories, Rising Pharmaceuticals, Sciegen Pharmaceuticals and Teva Pharmaceuticals.
“Today’s approval of the first generics for pregabalin, a widely used medication, is another example of the FDA’s long-standing commitment to advance patient access to lower cost, high quality generic medicines,” said Janet Woodcock, MD, director of the FDA’s Center for Drug Evaluation and Research.
More articles on pharmacy:
Oklahoma opioid trial wraps: 10 takeaways
Drugmaker tried to shred records before FDA inspection, agency claims
Publix Pharmacy to deliver prescriptions to patients before hospital discharge
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
